As of Wednesday close, Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) stock was up $0.41, moving up 3.98 percent to $10.70. The average number of shares traded per day over the past five days has been 9,653,720 shares. 4 times new highs have been achieved over the past 5 days, with a $0.37 gain in that time frame. In the last twenty days, the average volume was 7,897,955, while in the previous 50 days, it was 9,320,850.
Since last month, TEVA stock rose 11.34%. Shares of the company fell to $9.26 on 09/07/23, the lowest level in the past month. A 52-week high of $11.44 was reached on 01/12/23 after having rallying from a 52-week low of $7.09. Since the beginning of this year, TEVA’s stock price has risen by 17.32% or $1.58, and marked a new high 5 times. However, the stock has declined by -6.51% since its 52-week high.
TEVA stock investors should be aware that Teva Pharmaceutical Industries Limited (TEVA) stock had its last reported insider trading activity 45 days ago on Aug 07. Kalif Eliyahu Sharon, the EVP, Chief Financial Officer of the company, disposed of 35,125 shares for $9.73 on Aug 07. It resulted in a $341,889 divestment by the insider. Weiss Amir sold 1,981 shares at an average price of $9.92 on Aug 04. The insider now owns 42,442 shares following the transaction. On Aug 01, Hughes Eric A sold 52,742 shares at $8.30 apiece. The transaction was valued at $437,690.
Valuation Metrics
The stock’s beta is 1.16. Besides these, the trailing price-to-sales (P/S) ratio of 0.80, the price-to-book (PB) ratio of 1.70, and the price-to-cash flow ratio of 10.18 may also be considered.
The latest dividend of $0.0850 per share was paid out, remained unchanged from last year’s $0.0850.
Financial Health
In the three months ended June 29, Teva Pharmaceutical Industries Limited’s quick ratio stood at 0.70, while its current ratio was 1.00, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 2.65, and the total debt-to-equity ratio was 2.93. On the profitability front, the trailing twelve-month gross margin is 49.10% percent. In the year ended June 29, EBITDA margin amounted to 26.73%, whereas operating margins totaled -7.20%. Based on annual data, TEVA earned $6.97 billion in gross profit and brought in $14.93 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -5.00%. Return on equity (ROE) for the past 12 months was -28.30%.
In Teva Pharmaceutical Industries Limited’s quarter-end financial report for June 29, it reported total debt of $18.7 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. TEVA’s revenue rose 2.37% to $3.66 billion during the quarter, while net income inched up to $3.88 billion. While analysts expected Teva Pharmaceutical Industries Limited to report $0.52 quarterly earnings, the actual figure was $0.56 per share, beating the consensus estimate by 7.70%. During the quarter, the company generated -$346.0 million in EBITDA. The liabilities of Teva Pharmaceutical Industries Limited were 35.39 billion at the end of its most recent quarter ended June 29, and its total debt was $21.02 billion. The value of shareholders’ equity is $1.12 billion.
Technical Picture
This quick technical analysis looks at Teva Pharmaceutical Industries Limited’s (TEVA) price momentum. With a historical volatility rate of 41.77%, the RSI 9-day stood at 70.95% on 20 September.
With respect to its five-day moving average, the current Teva Pharmaceutical Industries Limited price is up by +3.58% percent or $0.37. At present, TEVA shares trade +9.74% above its 20-day simple moving average and +25.59% percent above its 100-day simple moving average. However, the stock is currently trading approximately +31.61% above its SMA50 and +22.99% above its SMA200.
Stochastic coefficient K was 87.88% and Stochastic coefficient D was 89.76%, while ATR was 0.26. Given the Stochastic reading of 98.63% for the 14-day period, the RSI (14) reading has been calculated as 69.40%. As of today, the MACD Oscillator reading stands at 0.21, while the 14-day reading stands at 0.46.
Analyst Ratings
UBS upgraded its rating on Teva Pharmaceutical Industries Limited (NYSE: TEVA) to a Neutral in a note to investors on July 06, 2023. The analysts firm previously had a Sell rating on the stock.Teva Pharmaceutical Industries Limited (TEVA) has been rated Hold by analysts. According to 2 brokerage firms, TEVA is a sell, and 8 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Teva Pharmaceutical Industries Limited stock as buy, with 2 recommending it as overweight.
With a median target price of $10.50, the current consensus forecast for the stock is $8.00 – $14.00. Based on these forecasts, analysts predict Teva Pharmaceutical Industries Limited (TEVA) will achieve an average price target of $10.75.
